European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
18F-FDG brain PET hypometabolism in patients with long COVID	300
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET	217
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres	162
Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT	153
The EANM practice guidelines for parathyroid imaging	136
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients	131
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0	122
Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study	112
Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT	112
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3	107
The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study	107
68Ga-FAPI-PET/CT in patients with various gynecological malignancies	105
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands	98
Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers	98
Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation	97
Cellular sources of TSPO expression in healthy and diseased brain	95
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds	94
Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT	91
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers	89
Deep learning-assisted ultra-fast/low-dose whole-body PET/CT imaging	89
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy	89
State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis	89
Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imagin	83
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI	82
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model	82

EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging	81
Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer	77
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports	75
18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma	71
A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study	70
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging	70
Large language models (LLM) and ChatGPT: what will the impact on nuclear medicine be?	69
Radiomics analysis of [18F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma	69
Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging	69
Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis	68
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)	68
Transpathology: molecular imaging-based pathology	67
Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma	67
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy	67
Structural and functional radiomics for lung cancer	66
Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis	65
Brain 18F-FDG PET for the diagnosis of autoimmune encephalitis: a systematic review and a meta-analysis	65
Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis	65
Quantification of amyloid PET for future clinical use: a state-of-the-art review	65
[18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04	63
Long axial field of view PET scanners: a road map to implementation and new possibilities	63
The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG	62
Ultra-low-activity total-body dynamic PET imaging allows equal performance to full-activity PET imaging for investigating kinetic metrics of 18F-FDG in healthy volunteers	62
Similar patterns of [18F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series	62
[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma	62
CXCR4-targeted theranostics in oncology	62
First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients	61
[11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates	60
Joint EANM/SNMMI guideline on radiomics in nuclear medicine	60
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0	59
Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis	59
Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study	59
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond	58
Hybrid total-body pet scanners—current status and future perspectives	58
Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer	57
Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer	57
Multi-scale optoacoustic molecular imaging of brain diseases	56
Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carc	56
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns	54
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer	52
Image quality and lesion detectability in low-dose pediatric 18F-FDG scans using total-body PET/CT	51
Total-body 18F-FDG PET/CT scan in oncology patients: how fast could it be?	50
Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation	49
Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure	48
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis	48
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics	47
[68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT	47
Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review	47
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria	47
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)	47

Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients	46
Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study	46
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework	46
Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer	46
The added value of PSMA PET/MR radiomics for prostate cancer staging	45
Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study	45
Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA	45
Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer	45
Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell	45
Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT	44
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome	44
A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study	44
Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer	44
Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis	44
Use of radiomics based on 18F-FDG PET/CT and machine learning methods to aid clinical decision-making in the classification of solitary pulmonary lesions: an innovative approach	44
New PET technologies – embracing progress and pushing the limits	43
[68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity	43
Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity	42
A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer’s disease, and mild cognitive impairment using brain 18F-FDG PET	41
PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival	40
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies	40
How molecular imaging will enable robotic precision surgery	40
Deep learning-based image reconstruction and post-processing methods in positron emission tomography for low-dose imaging and resolution enhancement	40
Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas	40
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group	40
Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary pro	39
TSPO imaging in animal models of brain diseases	39
Targeted optical fluorescence imaging: a meta-narrative review and future perspectives	39
Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment	39
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients	39
Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance	39
Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms	38
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	38
Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging	38
Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy	38
EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM)	38
Equivalent tumor detection for early and late FAPI-46 PET acquisition	37
Relationship between amyloid and tau levels and its impact on tau spreading	37
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [18F]FDG PET/CT and MRI	37
Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes	37
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of mela	36
[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation	36
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework	36
ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053	36
EANM practice guideline for quantitative SPECT-CT	35
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework	35
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies	35
[18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers	35
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors	35
Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients	35
Real-time intraoperative glioma diagnosis using fluorescence imaging and deep convolutional neural networks	35
GPC3-targeted immunoPET imaging of hepatocellular carcinomas	35
FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies	34
True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation	34
Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT	34
Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A	33
Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma	33
Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer	33
Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain	33
AI-enhanced simultaneous multiparametric 18F-FDG PET/MRI for accurate breast cancer diagnosis	33
Higher accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC	33
Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the “flare phenomenon” to the “abscopal effect”	32
18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention	32
Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics	32
[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer	32
18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results	32
Global experience with PSMA-based alpha therapy in prostate cancer	32
Image enhancement of whole-body oncology [18F]-FDG PET scans using deep neural networks to reduce noise	32
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment	31
Diagnostic performance of preoperative [18F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study	31
Distinguishing nontuberculous mycobacteria from Mycobacterium tuberculosis lung disease from CT images using a deep learning framework	31
A comprehensive review of imaging findings in COVID-19 - status in early 2021	31
Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent	31
The EANM guideline for radiosynoviorthesis	31
177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial	31
Parametric image generation with the uEXPLORER total-body PET/CT system through deep learning	31
To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer	31
Cyclotron production of 225Ac from an electroplated 226Ra target	31
Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma	31
Deep learning radiomics of dual-energy computed tomography for predicting lymph node metastases of pancreatic ductal adenocarcinoma	30

Decentralized collaborative multi-institutional PET attenuation and scatter correction using federated deep learning	30
Multivariate radiomics models based on 18F-FDG hybrid PET/MRI for distinguishing between Parkinson’s disease and multiple system atrophy	30
COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma	30
The impact of demographic, clinical, genetic, and imaging variables on tau PET status	30
Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond	30
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)	30
Kinetic metrics of 18F-FDG in normal human organs identified by systematic dynamic total-body positron emission tomography	30
Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer	30
Visual interpretation of brain hypometabolism related to neurological long COVID: a French multicentric experience	29
EANM position paper on the role of radiobiology in nuclear medicine	29
NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system	29
Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy	29
Deep learning–based denoising of low-dose SPECT myocardial perfusion images: quantitative assessment and clinical performance	29
Short-time total-body dynamic PET imaging performance in quantifying the kinetic metrics of 18F-FDG in healthy volunteers	29
PET imaging of neural activity, β-amyloid, and tau in normal brain aging	29
Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre	29
A cross-scanner and cross-tracer deep learning method for the recovery of standard-dose imaging quality from low-dose PET	29
Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients	29
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer	28
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia	28
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT—not only an FDG finding	28
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease	28
Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning	28
Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer—first clinical experiences	28
Pharmacokinetic studies of [68 Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type	28
A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer	28
Artificial intelligence is a promising prospect for the detection of prostate cancer extracapsular extension with mpMRI: a two-center comparative study	28
PET/MRI assessment of lung nodules in primary abdominal malignancies: sensitivity and outcome analysis	28
Direct and indirect strategies of deep-learning-based attenuation correction for general purpose and dedicated cardiac SPECT	28
Deep learning-based auto-delineation of gross tumour volumes and involved nodes in PET/CT images of head and neck cancer patients	28
Sensitive and specific detection of breast cancer lymph node metastasis through dual-modality magnetic particle imaging and fluorescence molecular imaging: a preclinical evaluation	28
PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the “Cancer Integrin” αvβ6 with Ga-68-Trivehexin	27
Inflammatory response in lungs and extrapulmonary sites detected by [18F] fluorodeoxyglucose PET/CT in convalescing COVID-19 patients tested negative for coronavirus	27
Advances in aptamer-based nuclear imaging	27
A deep learning framework for 18F-FDG PET imaging diagnosis in pediatric patients with temporal lobe epilepsy	27
[68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease	27
Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies	27
[18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial	27
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy	27
Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy	27
Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms	26
Evidence-based guideline of the European Association of Nuclear Medicine (EANM) on imaging infection in vascular grafts	26
Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma	26
68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours	26
In vivo methods for imaging blood–brain barrier function and dysfunction	26
Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps	26
Imaging of the glioma microenvironment by TSPO PET	26
PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions	26
Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy	26
Weakly supervised deep learning for determining the prognostic value of 18F-FDG PET/CT in extranodal natural killer/T cell lymphoma, nasal type	26
Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0	26
CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather	26
Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review	26
Prediction of H3K27M-mutant brainstem glioma by amide proton transfer–weighted imaging and its derived radiomics	26
A pure nanoICG-based homogeneous lipiodol formulation: toward precise surgical navigation of primary liver cancer after long-term transcatheter arterial embolization	26
Harmonisation of PET/CT contrast recovery performance for brain studies	26
Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting	26
Diagnostic accuracy of stress-only myocardial perfusion SPECT improved by deep learning	26
Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy	26
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials	25
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals	25
68Ga-FAPI PET visualize heart failure: from mechanism to clinic	25
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer	25
Imaging joint infections using D-methyl-11C-methionine PET/MRI: initial experience in humans	25
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease	25
Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer	25
Abbreviated scan protocols to capture 18F-FDG kinetics for long axial FOV PET scanners	25
Diagnostic performance of deep learning models for detecting bone metastasis on whole-body bone scan in prostate cancer	25
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand the	25
A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET/CT	24
Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography	24
Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience	24
Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients	24
The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study	24
Multi-antitumor therapy and synchronous imaging monitoring based on exosome	24
Evaluation of pediatric malignancies using total-body PET/CT with half-dose [18F]-FDG	24
The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging	24
EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0	24
Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer’s disease	24
The “digital biopsy” in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT	24
Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE	23
Supervised clustering for TSPO PET imaging	23
EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data	23
68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement	23
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study	23
Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET/CT in patients with primary prostate cancer	23
Why bother with alpha particles?	23
Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies	23
Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer	23
Active uptake of 68Ga-FAPI in Crohn’s disease but not in ulcerative colitis	23
Intraoperative fluorescence molecular imaging accelerates the coming of precision surgery in China	23
Brain 18F-FDG PET imaging in outpatients with post-COVID-19 conditions: findings and associations with clinical characteristics	22
Deep learning–based time-of-flight (ToF) image enhancement of non-ToF PET scans	22
ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer	22
Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival	22